The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma
Open accessAbstract
Nanoparticle-based materials, such as drug delivery vehicles and diagnostic probes, currently under evaluation in oncology clinical trials are largely not tumor selective.To be clinically successful, the next generation of nanoparticle agents should be tumor selective, nontoxic, and exhibit favorable targeting and clearance profiles.Developing probes meeting these criteria is challenging, requiring comprehensive in vivo evaluations.Here, we describe our full characterization of an approximately 7-nm diameter multimodal silica nanoparticle, exhibiting what we believe to be a unique combination of structural, optical, and biological properties.This ultrasmall cancer-selective silica particle was recently approved for a first-in-human clinical trial.Optimized for efficient renal clearance, it concurrently achieved specific tumor targeting.Dye-encapsulating particles, surface functionalized with cyclic arginine-glycine-aspartic acid peptide ligands and radioiodine, exhibited high-affinity/avidity binding, favorable tumor-to-blood residence time ratios, and enhanced tumor-selective accumulation in α v β 3 integrin-expressing melanoma xenografts in mice.Further, the sensitive, real-time detection and imaging of lymphatic drainage patterns, particle clearance rates, nodal metastases, and differential tumor burden in a large-animal model of melanoma highlighted the distinct potential advantage of this multimodal platform for staging metastatic disease in the clinical setting.and comprehensively defined according to the following set of diagnostic criteria: favorable distribution and targeting kinetics (1, 5-9), efficient renal clearance (10, 11), extended circulation (blood residence) times (5, 12, 13), pronounced tissue signal amplification (5, 6, 14), and improved tumoral penetration (15).Recently reported design criteria have been proposed for advancing targeted probes to the clinic (11).These have largely been restricted to improving renal clearance properties of inorganic particles containing inherently toxic components.The relative lack of in vivo toxicology data associated with these probes has led to persistent and valid safety concerns ( 16), prompting a number of particle-design modifications (9, 17-19), including size, composition, and surface chemistry, that promote more rapid clearance through kidney (renal) or liver (hepatic) pathways (20).While such approaches may minimize toxicity, the ultimate fate and impact of residual particles in the reticuloendothelial system (RES; liver, spleen, lymph nodes, bone marrow) remains unclear, particularly if toxicity is related to prolonged organ residence times (16, 17).Accelerated particle clearance may also preclude certain clinical applications as a result of restrictions imposed upon the available imaging period.Further, while rapid particle extravasation may facilitate clearance and delivery to tumors, reduced receptor binding (5) and increased nonspecific tissue dispersal (21, 22) may also occur, increasing image background and, potentially, toxicity by prolonging retention.Only a relatively small percentage of new imaging agents undergoing comprehensive preclinical testing potentially satisfy diagnostic criteria for translation (2).Although a number of fluo-Authorship note: Miriam Benezra and Oula Penate-Medina contributed equally to this work.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Imaging in the era of molecular oncology
Weissleder, R., & Pittet, M. J. (2008) · Nature · doi:10.1038/nature06917 · Cited by 2,364
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping
Kim, S., Lim, Y. T., Soltesz, E. G., De Grand, A. M., Lee, J., Nakayama, A., Parker, J. A., Mihaljevic, T., Laurence, R. G., Dor, D. M., et al. (2004) · Nature Biotechnology · doi:10.1038/nbt920 · Cited by 2,087
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,350
Weissleder, R. (2006) · Science · doi:10.1126/science.1125949 · Cited by 1,112
Preparation of monodisperse silica particles: Control of size and mass fraction
Bogush, G. H., Tracy, M. A., & Zukoski, C. F. (1988) · Journal of Non-Crystalline Solids · doi:10.1016/0022-3093(88)90187-1 · Cited by 1,103
Near-infrared fluorescence: application to in vivo molecular imaging
Hilderbrand, S. A., & Weissleder, R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.09.029 · Cited by 1,023
Bright and Stable Core−Shell Fluorescent Silica Nanoparticles
Ow, H., Larson, D. R., Srivastava, M., Baird, B. A., Webb, W. W., & Wiesner, U. (2005) · Nano Letters · doi:10.1021/nl0482478 · Cited by 932
Self-citationBurns, A., Ow, H., & Wiesner, U. (2006) · Chem. Soc. Rev. · doi:10.1039/b600562b · Cited by 849
Self-citationDesign considerations for tumour-targeted nanoparticles
Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2009.314 · Cited by 754
Nanotoxicity: the growing need for in vivo study
Fischer, H. C., & Chan, W. C. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.11.008 · Cited by 717
Specific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn
Cristy, M., & Eckerman, K. F. (1987) · doi:10.2172/6202949 · Cited by 692
Haubner, R., Wester, H. J., Weber, W., Mang, C., Ziegler, S. I., Goodman, S. L., Senekowitsch–Schmidtke, R., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 563
MIRD primer for absorbed dose calculations
LOEVINGER, R., Budinger, T. F., & Watson, E. E. (1988) · Medical Entomology and Zoology · Cited by 552
Kumar, R., Roy, I., Ohulchanskky, T. Y., Vathy, L. A., Bergey, E. J., Sajjad, M., & Prasad, P. N. (2010) · ACS Nano · doi:10.1021/nn901146y · Cited by 548
Alric, C., Taleb, J., Le Duc, G., Mandon, C., Billotey, C., Le Meur-Herland, A., Brochard, T., Vocanson, F., Janier, M., Perriat, P., et al. (2008) · Journal of the American Chemical Society · doi:10.1021/ja078176p · Cited by 541
Fluorescent Silica Nanoparticles with Efficient Urinary Excretion for Nanomedicine
Burns, A. A., Vider, J., Ow, H., Herz, E., Penate-Medina, O., Baumgart, M., Larson, S. M., Wiesner, U., & Bradbury, M. (2009) · Nano Letters · doi:10.1021/nl803405h · Cited by 474
Self-citationSchipper, M. L., Iyer, G., Koh, A. L., Cheng, Z., Ebenstein, Y., Aharoni, A., Keren, S., Bentolila, L. A., Li, J., Rao, J., et al. (2009) · Small · doi:10.1002/smll.200800003 · Cited by 452
Nano-sized MRI contrast agents with dendrimer cores
KOBAYASHI, H., & BRECHBIEL, M. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.016 · Cited by 437
In vivo Quantum‐Dot Toxicity Assessment
Hauck, T. S., Anderson, R. E., Fischer, H. C., Newbigging, S., & Chan, W. C. W. (2010) · Small · doi:10.1002/smll.200900626 · Cited by 428
Zimmer, J. P., Kim, S.-W., Ohnishi, S., Tanaka, E., Frangioni, J. V., & Bawendi, M. G. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0579816 · Cited by 406
Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display
Montet, X., Funovics, M., Montet-Abou, K., Weissleder, R., & Josephson, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060515m · Cited by 388
Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.
Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A., & Cheresh, D. A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115811 · Cited by 378
Heath, J. R., & Davis, M. E. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061506.185523 · Cited by 354
Sentinel Lymph Node Imaging Using Quantum Dots in Mouse Tumor Models
Ballou, B., Ernst, L. A., Andreko, S., Harper, T., Fitzpatrick, J. A. J., Waggoner, A. S., & Bruchez, M. P. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060261j · Cited by 344
Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour, L. W. (1992) · PubMed · Cited by 316
Specific absorbed fractions of energy at various ages from internal photon sources: 1, Methods
Cristy, M., & Eckerman, K. F. (1987) · doi:10.2172/6233735 · Cited by 310
Specific Targeting, Cell Sorting, and Bioimaging with Smart Magnetic Silica Core–Shell Nanomaterials
Yoon, T., Yu, K. N., Kim, E., Kim, J. S., Kim, B. G., Yun, S., Sohn, B., Cho, M., Lee, J., & Park, S. B. (2006) · Small · doi:10.1002/smll.200500360 · Cited by 307
Tanaka, E., Choi, H. S., Fujii, H., Bawendi, M. G., & Frangioni, J. V. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9194-6 · Cited by 262
Li, Z.-B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., & Chen, X. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.039859 · Cited by 251
Nanoparticle Imaging of Integrins on Tumor Cells
Montet, X., Montet-Abou, K., Reynolds, F., Weissleder, R., & Josephson, L. (2006) · Neoplasia · doi:10.1593/neo.05769 · Cited by 251
Molecular imaging and therapy of cancer with radiolabeled nanoparticles
Hong, H., Zhang, Y., Sun, J., & Cai, W. (2009) · Nano Today · doi:10.1016/j.nantod.2009.07.001 · Cited by 244
Silica Nanoparticle Architecture Determines Radiative Properties of Encapsulated Fluorophores
Larson, D. R., Ow, H., Vishwasrao, H. D., Heikal, A. A., Wiesner, U., & Webb, W. W. (2008) · Chemistry of Materials · doi:10.1021/cm7026866 · Cited by 237
Self-citationPoethko, T., Schottelius, M., Thumshirn, G., Hersel, U., Herz, M., Henriksen, G., Kessler, H., Schwaiger, M., & Wester, H. (2004) · PubMed · Cited by 227
Hybrid PET-optical imaging using targeted probes
Nahrendorf, M., Keliher, E., Marinelli, B., Waterman, P., Feruglio, P. F., Fexon, L., Pivovarov, M., Swirski, F. K., Pittet, M. J., Vinegoni, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915163107 · Cited by 222
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
Kelloff, G. J., Krohn, K. A., Larson, S. M., Weissleder, R., Mankoff, D. A., Hoffman, J. M., Link, J. M., Guyton, K. Z., Eckelman, W. C., Scher, H. I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1302 · Cited by 220
Self-citationImaging of integrin αvβ3 expression
Beer, A. J., & Schwaiger, M. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9158-3 · Cited by 211
Ohnishi, S., Lomnes, S. J., Laurence, R. G., Gogbashian, A., Mariani, G., & Frangioni, J. V. (2005) · Molecular Imaging · doi:10.1162/15353500200505127 · Cited by 210
Aharoni, A., Mokari, T., Popov, I., & Banin, U. (2006) · Journal of the American Chemical Society · doi:10.1021/ja056326v · Cited by 196
Multimodal Nanoprobes for Radionuclide and Five-Color Near-Infrared Optical Lymphatic Imaging
Kobayashi, H., Koyama, Y., Barrett, T., Hama, Y., Regino, C. A. S., Shin, I. S., Jang, B.-S., Le, N., Paik, C. H., Choyke, P. L., et al. (2007) · ACS Nano · doi:10.1021/nn700062z · Cited by 186
Kimura, R. H., Cheng, Z., Gambhir, S. S., & Cochran, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2495 · Cited by 158
MIRD : radionuclide data and decay schemes
Weber, D. A., & Dillman, L. T. (1989) · Society of Nuclear Medicine eBooks · Cited by 141
Core-shell silica nanoparticles as fluorescent labels for nanomedicine
Choi, J., Burns, A., Williams, R. M., Zhou, Z., Flesken‐Nikitin, A., Zipfel, W. R., Wiesner, U. B., & Nikitin, A. Y. (2007) · Journal of Biomedical Optics · doi:10.1117/1.2823149 · Cited by 127
Self-citationNear-Infrared Optical Imaging of Integrin α v β 3 in Human Tumor Xenografts
Wang, W., Shi, K., Wu, Q., Charnsangavej, C., Gurfinkel, M., Gelovani, J. G., Abbruzzese, J. L., Sevick-Muraca, E. M., & Li, C. (2004) · Molecular Imaging · doi:10.1162/1535350042973481 · Cited by 103
Alcoholic Solvent Effect on Silica Synthesis—NMR and DLS Investigation
Sadasivan, S., Dubey, A. K., Li, Y., & Rasmussen, D. H. (1998) · Journal of Sol-Gel Science and Technology · doi:10.1023/a:1008659708390 · Cited by 70
Drickamer, L. C. (1995) · Journal of Chemical Ecology · doi:10.1007/bf02035147 · Cited by 63
Immunotoxin Conjugation Techniques
Hermanson, G. T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-370501-3.00021-7 · Cited by 60
Nanoparticles in Biomedical Imaging
Bulte, J. W. M., & Modo, M. (2007) · Fundamental biomedical technologies · doi:10.1007/978-0-387-72027-2 · Cited by 50
Haubner, R., Bruchertseifer, F., Bock, M. J., Kessler, H., Schwaiger, M., & Wester, H. J. (2004) · PubMed · doi:10.1267/nukl04010026 · Cited by 47
Lucignani, G. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1104-2 · Cited by 42
Binding and Uptake of RGD-Containing Ligands to Cellular α v β 3 Integrins
Cressman, S., Sun, Y. X., Maxwell, E. J., Fang, N., Chen, D. D. Y., & Cullis, P. R. (2008) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-008-9163-y · Cited by 34
Cited by
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,836
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Multifunctional nanoparticles for multimodal imaging and theragnosis
Lee, D.-E., Koo, H., Sun, I.-C., Ryu, J. H., Kim, K., & Kwon, I. C. (2012) · Chem. Soc. Rev. · doi:10.1039/c2cs15261d · Cited by 1,410
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Nanomaterials for In Vivo Imaging
Smith, B. R., & Gambhir, S. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00073 · Cited by 1,075
Metadata
- Authors
- Benezra, M., Penate-Medina, O., Zanzonico, P. B., Schaer, D., Ow, H., Burns, A., DeStanchina, E., Longo, V., Herz, E., Iyer, S., Wolchok, J., Larson, S. M., Wiesner, U., & Bradbury, M. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-07-01
- Volume
- 121
- Issue
- 7
- Pages
- 2768-2780
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2063443915
- Cited by
- 645
- References
- 51
- FWCI
- 26.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.